Identifying optimal chemotherapy (CT) utilization rates can drive improvements in quality of care. We report a benchmarking approach to estimate the optimal rate of perioperative CT for muscle-invasive bladder cancer (MIBC). The Ontario Cancer Registry and linked treated records were used to identify neoadjuvant and adjuvant CT rates among patients with MIBC during 2004-2013. Monte […]
Adrenal cortical carcinoma is an aggressive malignancy and typically heralds a poor prognosis. The oncocytic subtype of this neoplasm is rare but may be associated with more favorable outcomes. The Provincial Cancer Registry was searched for cases of adrenal cortical carcinoma between 1992 and 2017. Comprehensive chart reviews were performed and data gathered related to […]
The incidence of clinical benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) is increasing due to the aging population, resulting in a significant economic and quality of life burden. Transgenic and other mouse models have been developed to recreate various aspects of this multifactorial disease; however, methods to accurately quantitate urinary dysfunction and […]
Holmium endoscopic laser enucleation of the prostate (HoLEP) is a well-established alternative to traditional transurethral resection and open prostatectomy for the treatment of benign prostatic hyperplasia (BPH). We investigate the 1470 nm diode laser for enucleation as an alternative to HoLEP. The safety, efficacy, and initial outcomes of diode enucleation of the prostate (DiLEP), when […]
To identify the point prevalence of indwelling urinary catheters (IDCs) in adult inpatients in acute care hospitals, and to describe the indications for IDC insertion based on patient age, gender, specialty and hospital. Catheter-associated urinary tract infections (CAUTIs) are preventable healthcare-associated infections. IDC duration is the strongest predictor of CAUTI, and little is known about […]
To compare the utility of the systematic 12-core prostate biopsy (SB) combined with magnetic resonance imaging (MRI)-targeted lesion biopsy (MRI-TB) versus MRI-TB alone in the diagnosis of high PI-RADS lesions. Patients undergoing MRI-TB+SB for suspicious MRI lesions were retrospectively reviewed. These patients had a previous prostate biopsy and were evaluated with MRI to assess the […]
To test the association between statin use and prostate volume (PV) change over time using data from REDUCE, a 4-year randomized controlled trial testing dutasteride for prostate cancer chemoprevention. We identified men with a baseline negative prostate biopsy from REDUCE who did not undergo prostate surgery or develop prostate cancer over the trial period. Men […]
Several recent studies on metastatic castration-resistant prostate cancer (mCRPC) demonstrated an improved overall survival for black vs. white men. Radium-223 is FDA approved for mCRPC based upon a survival benefit in the ALSYMPCA trial, where 94% of participants were white. We identified a real-world population of mCRPC patients who received radium-223 to compare differences in […]
To develop a triage strategy to reduce negative and indeterminate multiparametric MRI (mpMRI) scans in patients at risk for prostate cancer (PCa). In this retrospective study, we evaluated 865 patients with no prior PCa diagnosis who underwent prostate mpMRI between 2009 and 2017. Age, prostate volume, PSA, and PSA density (PSAd) were assessed as predictors […]
Basel, Switzerland (UroToday.com) Dr. Mark Rubin briefly shared his thoughts on the future of metastatic prostate cancer in regards to biomarkers. He began his talk with some definitions of prognostic and predictive biomarkers. A prognostic biomarker is one that indicates an increased (or decreased) likelihood of a future clinical event, disease recurrence or progression in an identified […]
